PEOPLE TAKING GLP-1S have a reduced risk of heart attacks, strokes, and death from cardiovascular disease, according to a ...

The company behind popular weight-loss drugs failed to disclose millions of pounds it paid to healthcare groups and patient ...

Two weeks into the job, it’s clear that newly elected State Treasurer Brad Briner won’t shy away from taking action, even if ...

Lean mass constituted 30.8% of total body weight lost for adults who received a GLP-1 drug during a randomized controlled ...

Find out all you need to know about Ozempic and other weight loss drugs, including the dangers and side effects ...

In one study of people on liraglutide (Saxenda), those who lifted four times ... and bile duct problems, according to a review in JAMA Internal Medicine. Gallstones come with sudden, intense ...

Detailed price information for Lexaria Bioscience Corp (LEXX-Q) from The Globe and Mail including charting and trades.

Wegovy is a GLP-1 agonist containing semaglutide, the same active ingredient as Ozempic. While both medications share this ...

The Study will compare an oral version of liraglutide, formulated from the DehydraTECH-processing of Saxenda® ("DehydraTECH-liraglutide") to the conventional injected liraglutide (Saxenda®). Lexaria ...

liraglutide (Saxenda), didn’t work as well as the others, researchers found after reviewing data from dozens of clinical trials. The review also found that a GLP-1 drug still in development ...